PF-07220060 CDK4 inhibitor clinical trials

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

This study looks at a new drug, PF-07220060, combined with fulvestrant for advanced or metastatic breast cancer. It compares this combination to standard treatments to see if it's safe and effective for people whose cancer has progressed after previous therapies.